EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective

Nor Azmaniza Azizam iD, Mofakhar Hussain, Eric Nauenberg, Wei Chern Ang iD, Amirah Azzeri, Jacob Smith iD

PLOS ONE · 06.09.2024 · 19 (9) · e0307234

DOI: 10.1371/journal.pone.0307234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 06.09.2024. Verfasst von Nor Azmaniza Azizam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Psoriasis, Cost-Benefit Analysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In Malaysia, there is now a dearth of recommendations pertaining to the priority of biologic treatments for the effective management of psoriasis, given the multitude of available therapeutic alternatives. Present analysis reports results of a cost-effectiveness model that determines the most optimal arrangement of biologic treatments, with a particular focus of adding biosimilars to the existing treatment pathway for psoriasis in Malaysia.

Methods

A Markov model was developed to compare the cost effectiveness of various biologic sequential treatments in a hypothetical cohort of moderate to severe psoriasis patient in Malaysia over a lifetime horizon. The model simulated the progression of patients through three lines of active biologic therapy, before transitioning to best supportive care. Costs and effects were discounted annually at a rate of 3%.

Results

First line secukinumab has produced lowest incremental cost effectiveness ratios (ICERs) when compared to first line systemic [ICERs value; US$152,474 (first set analysis) and US$110,572 (second set analysis)] and first line phototherapy [ICERs value; US$147,057 (first set analysis) and US$107,616 (second set analysis)]. However, these values were slightly higher than the Malaysian based threshold of three times gross domestic product per capita, US$104,337. A 40% reduction in the unit costs of reference biologics renders most of the evaluated treatment sequences cost-effective.

Conclusion

Adding biosimilar to the current treatment sequence could achieve cost savings ranging from 4.3% to 10.8% without significant loss of effectiveness. Given the significant impact of comorbidities and the resulting decline in quality of life among individuals with psoriasis, it may be justifiable to establish a threshold of up to US$184,000 per quality-adjusted life year (QALY) for the provision of therapies in the context of Malaysia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisCost-Benefit AnalysisHumansMalaysiaMarkov ChainsAntibodies, Monoclonal, HumanizedQuality-Adjusted Life YearsBiosimilar PharmaceuticalsMaleSeverity of Illness IndexDelivery of Health CareBiological ProductsCost-Effectiveness Analysis

Substanzen

Antibodies, Monoclonal, HumanizedsecukinumabBiosimilar PharmaceuticalsBiological Products

Autor:innen und Institutionen

  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
  • Faculty of Business and Management, Universiti Teknologi MARA Puncak Alam Campus, Selangor, Malaysia.
  • Clinical Research Centre, Ministry of Health Malaysia, Hospital Tuanku Fauziah, Kangar, Malaysia.
  • Department of Pharmacy, Hospital Tuanku Fauziah, Ministry of Health Malaysia, Kangar, Malaysia.
  • Faculty of Medicine and Health Sciences, Department of Primary Care, Public Health Unit, Universiti Sains Islam Malaysia, Nilai, Malaysia.

ORCID-Profile: Nor Azmaniza Azizam, Wei Chern Ang, Jacob Smith

Zitieren

APA

Azizam, N. A., Hussain, M., Nauenberg, E., Ang, W. C., Azzeri, A., & Smith, J. (2024). Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective. PLOS ONE, 19(9), e0307234. https://doi.org/10.1371/journal.pone.0307234

Vancouver

Azizam NA, Hussain M, Nauenberg E, Ang WC, Azzeri A, Smith J. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective. PLOS ONE. 2024;19(9):e0307234. doi:10.1371/journal.pone.0307234

BibTeX
@article{Azizam2024,
  author = {Azizam, Nor Azmaniza and Hussain, Mofakhar and Nauenberg, Eric and Ang, Wei Chern and Azzeri, Amirah and Smith, Jacob},
  title = {Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {9},
  pages = {e0307234},
  doi = {10.1371/journal.pone.0307234}
}
Kostenlos starten →